Yahoo Finance25d
LILLY'S TIRZEPATIDE SUPERIOR TO WEGOVY® (SEMAGLUTIDE) IN HEAD-TO-HEAD TRIAL SHOWING AN AVERAGE WEIGHT LOSS OF 20.2% VS. 13.7%
TORONTO, Dec. 4, 2024 /CNW/ - Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight ...
Yahoo Finance1mon
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss™ (lebrikizumab)
TORONTO, Nov. 19, 2024 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss™ (lebrikizumab ...
Business Insider1mon
Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss
Eli Lilly (LLY) Canada Inc. said it is disappointed and strongly disagrees with Canada’s Drug Agency’s Final Recommendation for Ebglyss, published on Friday, November 15, 2024. The CDA-AMC ...
Yahoo Finance25d
LILLY'S TIRZEPATIDE SUPERIOR TO WEGOVY® (SEMAGLUTIDE) IN HEAD-TO-HEAD TRIAL SHOWING AN AVERAGE WEIGHT LOSS OF 20.2% VS. 13.7%
TORONTO, Dec. 4, 2024 /CNW/ - Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight ...
The Globe and Mail1mon
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss™ (lebrikizumab)
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.